Lupus drug anifrolumab under safety microscope: infection and cancer risks tracked

NCT ID NCT07000110

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Mar 07, 2026 · Last updated May 14, 2026 · Updated 10 times

Summary

This study monitors about 3,200 adults with moderate-to-severe lupus to see if the drug anifrolumab raises the risk of serious infections or cancer compared to standard treatments. Researchers will analyze medical records over time, focusing on hospitalizations, infections needing IV antibiotics, and new cancer diagnoses. The goal is to better understand the drug's real-world safety profile.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Copenhagen, 23000, Denmark
Research Site
RECRUITING

Charenton-le-Pont, 94220, France
Research Site
RECRUITING

Essen, 45128, Germany
Research Site
RECRUITING

Barcelona, 08007, Spain

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC LUPUS ERYTHEMATOSUS